Abstract
Chronic cardiorenal syndrome (CRS) represents one of the five CRS in which renal dysfunction occurs in patients with chronic heart failure (HF). HF and chronic kidney disease (CKD) are a priori accompanied with high mortality and morbidity that can be further potentiated by their combination, while these conditions might be difficult to treat.
Gliflozins (SGLT2 inhibitors - sodium-glucose co-transporter-2) have been shown, based on results of large randomized trials, to be very effective therapeutics in treatment of all three phenotypic forms of HF (with reduced, mildly reduced and preserved ejection fraction, EF) and moreover have demonstrated their effectiveness in the treatment of patients with CKD. Their cardioprotective and renoprotective actions are very complex and offer novel treatment options in patients with chronic CRS that are discussed in this review article.